Methods: A retrospective chart review was performed at Children’s Health, Children's Medical Center of Dallas from January 1, 2013, to December 31, 2015. Pediatric oncology patients were eligible for inclusion if they received a minimum of 48 hours of combination therapy with V and PT or C, that were started within 48 hours of each other. Patients were excluded if they had pre-existing renal dysfunction, received vasopressors, or developed tumor lysis syndrome. Patient demographics, antibiotic dosing regimens, serum creatinine, and administration of concomitant nephrotoxic medications were recorded. The primary outcome was incidence of AKI according the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Descriptive statistics were used to compare the incidence of AKI and patient characteristics between the two groups.
Results: Of 613 patient charts reviewed, 39 met inclusion criteria (29 PT with V, 10 C with V). The median age of patients was 10 years [IQR 3.5 – 14]; median baseline serum creatinine was 0.4 mg/dL [IQR 0.3 – 0.65]. Characteristics between both groups were similar. Twenty-six (19 PT with V, 7 C with V) of the patients had an oncology diagnosis of leukemia (p = 0.795). KDIGO defined AKI occurred in 10 (34.5%) patients receiving PT with V and 2 (10%) patients receiving C with V (p = 0.392).
Conclusion: The results of this study support available literature and also suggest there may be an association between concurrent V and PT administration and increased risk of AKI in pediatric oncology patients.
M. Smith, None
K. Stewart, None
T. Laetsch Jr., None